David Roberts - LeMaitre Vascular President Director
| LMAT Stock | USD 99.06 0.83 0.84% |
President
Mr. David Brian Roberts serves as President, Director of Lemaitre Vascular, Inc. Mr. Roberts has served as our President since 2007 and as a member of our Board of Directors since 2001. Mr. Roberts joined us in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000, which position he held until 2007. From 1994 to 1997, Mr. Roberts held several positions at BUCA, Inc., an operator of Buca di Beppo restaurants, most recently serving as Vice President of Development and prior to that as Director of Finance. From 1992 to 1994, Mr. Roberts held several positions at Hancock Venture Partners, most recently serving as an Associate. Mr. Roberts received a B.A. in Business Economics and History from Brown University and an M.B.A. from the Stanford University Graduate School of Business. Mr. Roberts is a director of Parasole Restaurant Holdings, Inc., owner of several restaurants in the MinneapolisSt. Paul area including, among others, Mannys Steakhouse. The Board has concluded that Mr. Roberts should serve on our Board due to his extensive knowledge of our business, his responsibility within the organization for strategic transactions, and his thorough understanding of the industry in which we operate and the opportunities and challenges that we face. since 2007.
| Age | 61 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Address | 63 Second Avenue, Burlington, MA, United States, 01803 |
| Phone | 781 221 2266 |
| Web | https://www.lemaitre.com |
David Roberts Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Roberts against LeMaitre Vascular stock is an integral part of due diligence when investing in LeMaitre Vascular. David Roberts insider activity provides valuable insight into whether LeMaitre Vascular is net buyers or sellers over its current business cycle. Note, LeMaitre Vascular insiders must abide by specific rules, including filing SEC forms every time they buy or sell LeMaitre Vascular'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Roberts over three months ago Disposition of 51498 shares by David Roberts of Verra Mobility at 12.62 subject to Rule 16b-3 | ||
David Roberts over three months ago Disposition of 122 shares by David Roberts of LeMaitre Vascular at 23.56 subject to Rule 16b-3 | ||
David Roberts over six months ago Disposition of 5025 shares by David Roberts of LeMaitre Vascular at 75.62 subject to Rule 16b-3 | ||
David Roberts over six months ago Acquisition by David Roberts of 52447 shares of Verra Mobility subject to Rule 16b-3 |
LeMaitre Vascular Management Efficiency
The company has return on total asset (ROA) of 0.0872 % which means that it generated a profit of $0.0872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1334 %, meaning that it created $0.1334 on every $100 dollars invested by stockholders. LeMaitre Vascular's management efficiency ratios could be used to measure how well LeMaitre Vascular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.1 in 2025, whereas Return On Tangible Assets are likely to drop 0.06 in 2025. At this time, LeMaitre Vascular's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 418.7 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 1.8 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Auerbach | The Cooper Companies, | 58 | |
| Jennifer Schneiders | Hologic | 56 | |
| Michelle Basil | Haemonetics | 52 | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
| Stewart Strong | Haemonetics | 58 | |
| Holly Sheffield | The Cooper Companies, | 54 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Virginia Sanzone | ICU Medical | 50 | |
| William Burke | Haemonetics | 52 | |
| Jan Verstreken | Hologic | 57 | |
| Randal Golden | The Cooper Companies, | 57 | |
| James Darecca | Haemonetics | 50 | |
| Anila Lingamneni | Haemonetics | 57 | |
| Brian Andrews | The Cooper Companies, | 46 | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Daniel Woolson | ICU Medical | 48 | |
| James McAvinn | Milestone Scientific | N/A | |
| Roy Galvin | Haemonetics | 54 | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Daniel McBride | The Cooper Companies, | 56 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0872 |
LeMaitre Vascular Leadership Team
Elected by the shareholders, the LeMaitre Vascular's board of directors comprises two types of representatives: LeMaitre Vascular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LeMaitre. The board's role is to monitor LeMaitre Vascular's management team and ensure that shareholders' interests are well served. LeMaitre Vascular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LeMaitre Vascular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Roberts, President Director | ||
| Jonathan Ngau, Senior Technology | ||
| George LeMaitre, Chairman and CEO | ||
| Trent Kamke, Sr. VP of Operations | ||
| Kimberly Cieslak, Vice President - Marketing | ||
| Ryan Connelly, Vice President - Research & Development | ||
| Laurie Churchill, Senior Vice President General Counsel | ||
| Maik Helmers, Senior Europe | ||
| Joseph Pellegrino, CFO, Principal Accounting Officer and Secretary | ||
| Stephane Maier, Vice President EMEA Operations | ||
| Daniel Mumford, Director Resources | ||
| David Hissong, General Counsel | ||
| Andrew Hodgkinson, Senior Vice President - Clinical, Regulatory and Quality Affairs |
LeMaitre Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LeMaitre Vascular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.12 B | ||||
| Shares Outstanding | 22.48 M | ||||
| Shares Owned By Insiders | 8.87 % | ||||
| Shares Owned By Institutions | 93.68 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Earning | 38.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for LeMaitre Stock Analysis
When running LeMaitre Vascular's price analysis, check to measure LeMaitre Vascular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LeMaitre Vascular is operating at the current time. Most of LeMaitre Vascular's value examination focuses on studying past and present price action to predict the probability of LeMaitre Vascular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LeMaitre Vascular's price. Additionally, you may evaluate how the addition of LeMaitre Vascular to your portfolios can decrease your overall portfolio volatility.